Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series.

Foundation One (F1) MiNENs NGS analysis gastrointestinal tumors mixed neuroendocrine/non-neuroendocrine neoplasms

Journal

Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525

Informations de publication

Date de publication:
11 Apr 2022
Historique:
received: 20 03 2022
revised: 05 04 2022
accepted: 08 04 2022
entrez: 23 4 2022
pubmed: 24 4 2022
medline: 24 4 2022
Statut: epublish

Résumé

Mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) refer to heterogenous rare neoplasms constituted of at least a neuroendocrine population-either well-differentiated, or more frequently poorly differentiated-and a non-neuroendocrine population, both accounting for at least 30% of the whole tumor mass. Several studies recently focused on the key genetic and epigenetic changes underlying MiNENs to better understand how they develop, and explore biological similarities among the two components and their pure counterparts. However, their molecular landscape still remains poorly understood. NGS may represent a useful tool to study this orphan disease by detecting the main genetic alterations and possible therapeutic targets. NGS analysis on tissue and/or blood samples through the Foundation One (F1) platform was performed on consecutive samples collected from four patients diagnosed with MiNENs of the gastroenteric tract. Several genetic alterations were shared among samples from the same patients, thus suggesting a common origin between them, although morphology sometimes changed at histopathological evaluation. Common molecular alterations among samples from different patients that had not been previously described to our knowledge were also detected. Finally, it is of the utmost importance to clarify if the maintenance of the 30% cut-off is still essential in defining MiNENs and really manages to include all of the mixed neoplasms.

Identifiants

pubmed: 35455885
pii: healthcare10040708
doi: 10.3390/healthcare10040708
pmc: PMC9028985
pii:
doi:

Types de publication

Case Reports

Langues

eng

Références

Exp Mol Med. 2019 Dec 12;51(12):1-13
pubmed: 31827074
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
J Thorac Oncol. 2018 Jun;13(6):752-766
pubmed: 29454048
Hum Pathol. 2018 Mar;73:16-25
pubmed: 28899736
Cancers (Basel). 2012 Jan 16;4(1):11-30
pubmed: 24213223
Hum Pathol. 2021 Apr;110:1-10
pubmed: 33359239
Cancers (Basel). 2020 Jul 31;12(8):
pubmed: 32751889
J Clin Med. 2020 Jan 19;9(1):
pubmed: 31963850
Endocr Pathol. 2016 Dec;27(4):284-311
pubmed: 27169712
Neuroendocrinology. 2014;100(4):310-6
pubmed: 25342539
Mol Ther Oncolytics. 2020 Jan 10;16:188-196
pubmed: 32099898
Hum Pathol. 2010 Aug;41(8):1069-78
pubmed: 20381114
Neuroendocrinology. 2016;103(2):186-94
pubmed: 26731334
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Hum Pathol. 2018 Mar;73:184-191
pubmed: 29288693
Anticancer Res. 2014 Oct;34(10):5517-21
pubmed: 25275049
Mod Pathol. 2017 Apr;30(4):610-619
pubmed: 28059096
Gynecol Oncol. 2021 Jun;161(3):779-786
pubmed: 33888337
Am J Clin Pathol. 2013 Jul;140(1):61-72
pubmed: 23765535
Mod Pathol. 2017 Jan;30(1):95-103
pubmed: 27586204
Nat Rev Cancer. 2013 Jan;13(1):11-26
pubmed: 23258168
Histopathology. 2020 Nov;77(5):700-717
pubmed: 32538468
Neuroendocrinology. 2017;105(4):412-425
pubmed: 28803232

Auteurs

Luigi Pio Guerrera (LP)

Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", 80131 Napoli, Italy.

Gabriella Suarato (G)

Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", 80131 Napoli, Italy.

Rossella Napolitano (R)

Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", 80131 Napoli, Italy.

Alessandra Perrone (A)

Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", 80131 Napoli, Italy.

Vincenza Caputo (V)

Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", 80131 Napoli, Italy.

Anna Ventriglia (A)

Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", 80131 Napoli, Italy.

Giulia Martini (G)

Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", 80131 Napoli, Italy.

Carminia Maria Della Corte (CM)

Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", 80131 Napoli, Italy.

Michele Orditura (M)

Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", 80131 Napoli, Italy.

Erika Martinelli (E)

Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", 80131 Napoli, Italy.

Fortunato Ciardiello (F)

Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", 80131 Napoli, Italy.

Marco Montella (M)

Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, Università degli Studi della Campania "Luigi Vanvitelli", 80138 Napoli, Italy.

Renato Franco (R)

Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, Università degli Studi della Campania "Luigi Vanvitelli", 80138 Napoli, Italy.

Teresa Troiani (T)

Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", 80131 Napoli, Italy.

Stefania Napolitano (S)

Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", 80131 Napoli, Italy.

Classifications MeSH